BioAlliance Pharma : New Achievements in the Collaboration with Its Strategic European Partner, Therabel

January 04, 2012 - BioAlliance Pharma SA (Paris:BIO)(Euronext Paris - BIO), a company dedicated to specialty and orphan oncology products, today announces the achievement of the reserved capital increase and the payment of the €1 million milestone, as provided in the commercialization agreement signed with the Therabel Group for Loramyc® in Europe.

Therabel has actually subscribed for the maximum amount authorized by the General Assembly Meeting of June 29, 2011, i.e. 680.000 new shares, with a 15% premium over the last 20 business days preceding the operation (€3.65 per share).

Moreover, Therabel has finalized end of December 2011 the discussions with the Italian health authorities (Agenzia Italiana del Farmaco) regarding the price and the reimbursement for Loramyc®; publication in the Italian official journal should occur shortly. In this context, BioAlliance will receive from its partner an additional payment indexed on futures sales of Loramyc® in Italy up to a maximum amount of €500.000.

BioAlliance has received more than €11 million (royalties excluded) of which €3.5 million in 2011 since the signature of its partnership agreement with Therabel. An additional €1 million payment is planned end of 2012... BioAlliance Pharma's Press Release - Communiqués de Presse BioAlliance Pharma -